Shelf-Life Determination

The shelf-life of a pharmaceutical product is conventionally defined by the parameter t90, the time required for the intact drug content to decline to 90...

The shelf-life of a pharmaceutical product is conventionally defined by the parameter t90, the time required for the intact drug content to decline to 90 per cent of its labelled or initial value, reflecting the widely applied regulatory convention that a 10 per cent loss of potency represents the maximum acceptable degradation before a product is considered to have expired. For a drug substance following first-order degradation kinetics, t90 is calculated directly from the degradation rate constant through the relationship t90 equals 0.105 divided by k, a formula derived directly from the first-order integrated rate equation evaluated at the 90 per cent retention endpoint.

Where long-term stability data at the intended storage temperature is not yet available at the time shelf-life must be estimated — as is invariably the case during early development, when regulatory submission timelines require a shelf-life projection well before multi-year real-time data can be generated — the Arrhenius relationship is employed to predict the rate constant, and hence t90, at the intended storage temperature from data generated under accelerated conditions, using either an experimentally determined activation energy or, where this has not been separately established, a conservative literature-based estimate.

ICH Q1E provides the statistical framework governing the formal evaluation of stability data and the derivation of a regulatory shelf-life, specifying that the proposed shelf-life should be supported by a 95 per cent one-sided confidence interval for the mean degradation trend that remains within the approved specification limit throughout the proposed storage period, a statistically conservative approach that accounts for both the observed variability in the stability data and the uncertainty inherent in extrapolating beyond the period of directly observed data. Where multiple batches are available, ICH Q1E additionally provides statistical criteria for determining whether batch data can be pooled for the purpose of shelf-life estimation or must instead be evaluated individually, based on formal statistical tests of the homogeneity of degradation slopes and intercepts across batches.

The shelf-life ultimately assigned to a product, together with its recommended storage condition, represents the culmination of the entire stability programme, integrating the kinetic behaviour of the drug substance, the protective or degradative influence of the formulation and packaging system, and rigorous statistical analysis, and it is this figure — expressed on every product label as an expiry date — that provides patients and healthcare providers with the assurance that a medicine will retain its labelled potency and quality throughout its intended period of use.

Review Questions

1. List the ICH Q1A(R2) storage conditions and explain the purpose served by each.

2. Explain how stability protocols differ between solid, liquid, and parenteral dosage forms.

3. Distinguish zero-order, first-order, and second-order degradation kinetics and give a pharmaceutical example of each.

4. Derive and explain the significance of the t90 shelf-life calculation for a first-order degradation process.

5. Explain the role of the Arrhenius equation and ICH Q1E in shelf-life prediction and statistical evaluation.